Targeting SOD1 reduces experimental non–small-cell lung cancer

Approximately 85% of lung cancers are non–small-cell lung cancers (NSCLCs), which are often diagnosed at an advanced stage and associated with poor prognosis. Currently, there are very few therapies available for NSCLCs due to the recalcitrant nature of this cancer. Mutations that activate the small...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of clinical investigation 2014-01, Vol.124 (1), p.117-128
Hauptverfasser:	Glasauer, Andrea, Sena, Laura A, Diebold, Lauren P, Mazar, Andrew P, Chandel, Navdeep S
Format:	Artikel
Sprache:	eng
Schlagworte:	Aniline Compounds - pharmacology Animals Antineoplastic Agents - pharmacology Antioxidants Apoptosis Biomedical research Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - pathology Care and treatment Cell Adhesion Cell Line, Tumor Cell Proliferation - drug effects Complications and side effects Copper Development and progression Drug dosages Drug Screening Assays, Antitumor Drug Synergism Enzymes Health aspects Histology Humans Hydrogen Peroxide - metabolism Lung cancer Lung cancer, Non-small cell Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - pathology MAP Kinase Signaling System Mice Mice, Inbred C57BL Mice, Transgenic Molybdenum - pharmacology Mutation Myeloid Cell Leukemia Sequence 1 Protein - metabolism Prognosis Software Sulfonamides - pharmacology Superoxide Dismutase - antagonists & inhibitors Superoxide Dismutase - genetics Superoxide Dismutase - metabolism Superoxide Dismutase-1 Tumor Burden - drug effects Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!